| Pharmaceutical Information |
| Drug Name |
Becaplermin |
| Drug ID |
BADD_D00216 |
| Description |
Becaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae. Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical polypeptide chains that are bound together by disulfide bonds. |
| Indications and Usage |
For topical treatment of skin ulcers (from diabetes) |
| Marketing Status |
approved; investigational |
| ATC Code |
A01AD08; D03AX06 |
| DrugBank ID |
DB00102
|
| KEGG ID |
D03065
|
| MeSH ID |
D000077214
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0T5QT
|
| NDC Product Code |
63508-005; 50484-810 |
| UNII |
1B56C968OA
|
| Synonyms |
Becaplermin | Platelet-Derived Growth Factor BB, Recombinant | Platelet Derived Growth Factor BB, Recombinant | rPDGF-BB | PDGF-BB | rhPDGF-BB | Platelet-Derived Growth Factor BB | Platelet Derived Growth Factor BB | Recombinant Platelet-Derived Growth Factor BB | Recombinant Platelet Derived Growth Factor BB | Regranex |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
165101-51-9 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
